




































































































These signs and symptoms occur in the late stage of the 
disease
Radiographic and clinical signs are 
preceeded by a silent molecular phase






































…To diagnose the disease at the silent molecular phase
Drug discovery is protracted, risky and 
costly
Nothing new to offer at the 
patients and the OA research 
community
Clinical trials end-point




 Structure modification (1 to 3 years)
Imaging outcomes
Joint Space Narrowing
The main limitations of JSN 
 Indirect measure of the alteration in 
articular cartilage.
 Fails to measure a dynamic process
 Confounded by the presence of 
meniscal lesions and extrusion.
 Changes overtime are small, and occur 
in only a subset (progressors) of patients.
 Poorly reproducible (full extension).
 Poorly correlated with joint function and 
pain. 
Why do we need of biological
markers?
 To enrich our understanding of OA 
pathogenesis
 To detect early OA
 To discriminate progressor and non 
progressor
 To monitor progression of OA and 
efficacy of treatment
 To surrogate clinical end-point
















Soluble or « wet » biomarkers « Dry » biomarkers
A biomarker is a characteristic that is objectively
measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic
intervention. » 
Biomarkers Definitions Working Group I. Biomarkers and surrogate endpoints: preferred



































































 The most abundant protein in cartilage
 Relatively specific of hyaline cartilage
 Makes up only 1% of all collagens
 Collagen breakdown is a critical event





























Coll2-1NO2: a joint inflammation 
related biomarkers













FIBRILLATION ZONE CELL CLUSTER ZONE
Cleavage site of MMP-1, MMP-8 and MMP-13



















































Deberg M et al. New serum biochemical markers (Coll2-1 and Coll2-1NO2) for studying oxidative-related 
type II collagen network degradation in patients with OA and RA.Osteoarthritis Cart 2005; 13: 258-65.




























Diagnosis: COLL 2-1NO2 discriminates
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Lower probability to develop OA
Lower X-ray OA severity


























































































Rego-Perez I. et al ARD, 2010
*
Diagnosis: OA patients with haplogroup J 

































Serpins b1 et b3


















Specific immunoassays of Fib3-1 
and Fib3-2 development and 
validation in human serum
Fib 3-2:ROC curve












































Fib3-1 (cut-off:  71.1 pM) 78.5% 68.4%
































Fibulin-3 fragments (Fib3-1 and Fib3-2):  
potential diagnostic biomarkers
BIOVISCO study: Study design






1NO2, s C2C, sCOMP, 
sCS-846, sCPII, CTX-II,
Fib3-1, Fib3-2
Henrotin Y et al. Journal of Orthopaedic Research
19 FEB 2013
BIOVISCO study
An open label observational prospective study
Conrozier et al, J Orthp Res, 2012; Henrotin et al, J Orthp Res,2013.
D1 
(after the last injection)
90 days
(after the last injection)
p-Value
D1 vs D90
sColl2-1 (nM) 140.34(882.44-285.32) 128.41 (85.6-241.34) 0.05*
sColl2-1NO2 (nM) 0.400 (0.050-1.010) 0.370 (0.14-0.870) 0.025*
uCTX-II (ng/nmolcreat) 392.7 (90.0-816.4) 306.0 (90-1123.9) 0.02*
sPIICP (ng/ml) 817.9 (131.4-1848.6) 874.8.3 (326.4-1435.0) 0.41
sC2C (ng/ml) 223.6 (99.4-329) 209.5 (135.9-291.7) 0.11
sCOMP (U/L) 10.9 (6.0-20.2) 10.5 (6.0-20.0) 0.82
sCS846 (ng/ml) 99.8 (45.9-172.3) 102.2 (53.0-190) 0.38
sHA (ng/ml) 34.1 (15.4-211) 33.3 (9.5-230.1) 0.38
 45 patients with unilateral symptomatic tibiofemoral and/or patellofemoral OA
 3-weekly intraarticular injection of hyalan G20 (Synvisc®)
 Follow-up D1, D30 and D90 after the last injection
Future
Critical needs!
 Drugs that can impact the disease
progression
 Large cohorts representative of the general
population and designed for the 
qualification of the biomarkers
 A sensitive imaging gold standard detecting
early structural changing in joint tissues
 The inclusion of biomarkers as secondary
end-point in clinical trials
 New technologies adapted to a 
personalized management
 Combination of biomarkers in multiplex tests 
 Agregate score including clinical, imaging
and biological parameters
 Companion biomarkers for drugs
(Theranostic)
Short term perspectives
Thank you for your attention !
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